Literature DB >> 2269325

Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients.

Y Zhang1, M Schluep, S Frutiger, G J Hughes, M Jeannet, A Steck, T Barkas.   

Abstract

The response of human T lymphocytes against the nicotinic acetylcholine receptor (AChR) was studied in five patients with myasthenia gravis (MG) and in six healthy donors using either native Torpedo AChR or recombinant protein derived from the mammalian AChR alpha subunit (X4, residues 6-216 of mouse AChR alpha subunit). The present study demonstrates that (a) AChR-specific T helper cell lines can be generated from MG patients [either from peripheral blood lymphocytes (PBL) or from thymocytes] as well as from PBL of normal controls, (b) lymphocytes from MG patients, but not from controls, recognize the mammalian AChR but not the Torpedo receptor, (c) in humans, the HLA-DR2-associated T cell epitope is probably located in the region of residues 162-216 of the AChR alpha subunit and (d) there is a considerable heterogeneity of autoreactive T cell responses: (i) T cell lines from different HLA-type donors have distinct epitope profiles; (ii) the epitope specificity of the PBL-derived T cell line is different from that of the thymocyte-derived line; (iii) the epitope specificities of patient-derived T cell lines are different from those generated from normal controls who share the same HLA phenotype.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2269325     DOI: 10.1002/eji.1830201208

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Intrathymic expression of neuromuscular acetylcholine receptors and the immunpathogenesis of myasthenia gravis.

Authors:  Arnold I Levinson; Yi Zheng; Glen Gaulton; Decheng Song; Jonni Moore; C Hank Pletcher
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Overexpression of select T cell receptor V beta gene families within CD4+ and CD8+ T cell subsets of myasthenia gravis patients: a role for superantigen(s)?

Authors:  D Gigliotti; A K Lefvert; M Jeddi-Tehrani; S Esin; V Hodara; R Pirskanen; H Wigzell; R Andersson
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

Review 4.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 5.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Presentation of endogenous acetylcholine receptor antigen to a specific CD4+ T-cell line by a transfected B-cell line.

Authors:  A F Mulcahy; D M Beeson; N Willcox; A G Diamond
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

7.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.

Authors:  M P Protti; A A Manfredi; X D Wu; L Moiola; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.

Authors:  E Zisman; Y Katz-Levy; M Dayan; S L Kirshner; M Paas-Rozner; A Karni; O Abramsky; C Brautbar; M Fridkin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

9.  Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis.

Authors:  H Yssel; M C Shanafelt; C Soderberg; P V Schneider; J Anzola; G Peltz
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.